Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies

This roundtable focuses on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders. Listen as the panel discuss the adoption of biomarker strategies that can create efficiency in your clinical cell therapy development efforts, applying a precision medicine biomarker-driven strategy, flow cytometry applications for the development of adoptive cell therapies, analytical tools to assess CRS, neurotoxicity and unintended/intended events and comprehensive immune profiling applications including NGS, TCR β repertoire and HLA haplotype.